What additional diagnostics and management steps should be ordered for a patient with suspected post‑streptococcal glomerulonephritis who has already had a complete blood count (CBC) and urinalysis?

Additional Diagnostics and Management for Suspected Post-Streptococcal Glomerulonephritis

Beyond CBC and urinalysis, you should immediately order complement levels (C3, C4), anti-streptococcal antibody titers (ASO and anti-DNase B), renal function tests (serum creatinine/eGFR), and throat/skin cultures if infection is still present, while initiating supportive management with penicillin (or erythromycin if penicillin-allergic) even without active infection. 1

Essential Additional Laboratory Tests

Serologic Confirmation

• Anti-streptococcal antibodies: Order both anti-streptolysin O (ASO) and anti-DNase B titers, as anti-DNase B has higher sensitivity (86.9% positive) compared to ASO alone (72.7% positive) 2
• ASO titers confirm recent invasive streptococcal infection and should be obtained in all suspected cases 3
• Anti-DNase B is particularly important as it may be positive when ASO is negative 3

Complement Studies

• C3 complement level: This is the single most important diagnostic test—96.1% of APSGN patients show C3 hypocomplementemia 2
• C4 complement level: Should remain normal in APSGN (helps distinguish from other glomerulonephritides) 1
• Low C3 with normal C4 is characteristic of post-streptococcal disease 1

Renal Function Assessment

• Serum creatinine and eGFR: Essential to assess severity and guide management decisions 4, 5
• 24-hour urine protein or first morning protein-creatinine ratio: Quantify proteinuria to determine if nephrotic-range (which affects prognosis) 1
• Serum albumin: Hypoalbuminemia indicates nephrotic syndrome and correlates with disease severity 5

Additional Markers

• C-reactive protein (CRP): Elevated CRP is associated with disease severity 5
• Serum uric acid: May be markedly elevated in severe cases 6
• Throat or skin culture: If active infection suspected, though treatment should not be delayed pending results 1

Management Approach

Antibiotic Therapy

Treat with penicillin (or erythromycin if penicillin-allergic) even in the absence of persistent infection to decrease antigenic load 1. This is recommended despite the infection typically occurring 1-3 weeks prior to presentation 1.

Supportive Management of Nephritic Syndrome

• Fluid restriction: Critical for managing hypervolemia 4, 5
• Diuretics: For edema and volume overload management 1, 4
• Antihypertensives: To control blood pressure and prevent hypertensive complications 1, 4
• Dialysis: Reserve for severe acute kidney injury, refractory hypervolemia, or life-threatening complications 1, 4

Monitoring for Complications

Watch specifically for:

• Hypertensive emergencies and encephalopathy: Occurs due to hypervolemia in acute phase 5
• Congestive heart failure and pulmonary edema: Most common severe complication (23.4% of cases) 2
• Severe acute kidney injury: May require renal replacement therapy 4

When to Consider Kidney Biopsy

Kidney biopsy is NOT routinely needed for typical APSGN 1, 4. However, consider biopsy in these specific scenarios:

• Rapidly progressive glomerulonephritis with crescentic features: May warrant corticosteroids based on anecdotal evidence 1
• Atypical disease progression: Worsening renal function despite treatment 4
• Diagnostic uncertainty: When culture evidence is elusive or diagnosis is in doubt 1
• Persistent abnormalities: If hypertension, proteinuria, or impaired kidney function persist beyond 3 months 2

Immunosuppression Considerations

Corticosteroids are NOT routinely indicated for typical APSGN 1. They should only be considered for:

• Severe crescentic glomerulonephritis (based on anecdotal evidence only) 1
• Rapidly progressive disease confirmed on biopsy 4, 2

Important caveat: Distinguish IgA-dominant postinfectious GN (increasingly recognized variant, especially in elderly and diabetics with staphylococcal infections) from idiopathic IgA nephropathy, as the former should NOT be treated with corticosteroids 1.

Follow-up Monitoring

• At 4 weeks: Reassess clinical features, blood pressure, urinalysis, renal function 2
• At 12 weeks: Most clinical features should resolve by 3 months; persistent abnormalities (hypertension, proteinuria, impaired kidney function) occur in approximately 6.5% and warrant nephrology referral 2
• Long-term: Monitor for progression to chronic kidney disease, particularly in those with persistent proteinuria or crescent formation on biopsy 4, 5